Population examined:

Members in Omada for Prevention, Diabetes, and Hypertension programs with 12-month follow-up data

Summary:

Using a Markov model, this study estimated the reduction of disease onset and associated cost savings for Omada’s cardiometabolic programs. Estimated gross savings in medical expenditures across the programs in 2022 dollars were $892 to $1,342 after 1 year, and cumulative estimated gross medical savings were $2,963 to $4,346 after 3 years and $5,221 to $7,756 after 5 years.

Citation: Noble M, Chen F, Linke S, Dall TM, Napoleone J. Modeling the economic value of cardiometabolic virtual-first care programs. Am J Manag Care. 2024;30(6 Spec No.):SP430-SP436. doi:10.37765/ajmc.2024.89549